Chinese retail investors struggle to identify undervalued pharmaceutical stocks with explosive growth potential before they surge

Chinese stock market investors are desperately seeking ways to discover pharmaceutical companies with hidden growth catalysts (like non-innovative drugs with massive profit expansion) before these stocks become 10x winners. Current financial analysis tools and stock screening methods fail to surface these 'dark horse' opportunities early, causing investors to miss life-changing returns. The pain is acute because pharmaceutical stocks with 11x net profit growth are rare, and investors feel they're always entering too late.